Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 17/20 | 0.69 |
| ▸ | JAK1 | P23458 | 11/20 | 0.65 |
| ▸ | JAK2 | O60674 | 7/20 | 0.65 |
| ▸ | TYK2 | P29597 | 4/20 | 0.49 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | TTK | P33981 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | FLT3 | P36888 | 1/20 | 0.49 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28364413 | 1.00 | JAK3 (0.69) | JAK3JAK1JAK2TYK2MAP3K7 | |
| SCHEMBL21846865 | 0.91 | JAK3 (0.83) | JAK3JAK1JAK2TYK2MAP3K7 | |
| SCHEMBL29388365 | 0.91 | JAK3 (0.57) | JAK3JAK1JAK2TYK2TTK | |
| SCHEMBL21847334 | 0.91 | JAK3 (0.57) | JAK3JAK1JAK2TYK2TTK | |
| SCHEMBL28364421 | 0.91 | JAK3 (0.84) | JAK3JAK1JAK2TYK2MAP3K7 | |
| SCHEMBL21847096 | 0.91 | JAK3 (0.84) | JAK3JAK1JAK2TYK2MAP3K7 | |
| SCHEMBL21847331 | 0.87 | JAK3 (0.55) | JAK3JAK1JAK2TYK2MAP3K7 | |
| SCHEMBL29387383 | 0.87 | JAK3 (0.55) | JAK3JAK1JAK2TYK2MAP3K7 | |
| SCHEMBL24249375 | 0.83 | JAK3 (0.50) | JAK3JAK1JAK2MAPK1FLT3 | |
| SCHEMBL21847332 | 0.82 | JAK3 (0.46) | JAK3JAK1JAK2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220048914-A1 | PREPARATION FOR 6-AMINO-1H-PYRAZOLO[3,4-D]PYRIMIDINE-BASED JAK KINASE INHIBITOR AND APPLICATION THEREOF | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2022-02-17 | — | — | US | disclosed |
| WO-2020052489-A1 | PREPARATION FOR 6-AMINO-1H-PYRAZOLO[3,4-D]PYRIMIDINE-BASED JAK KINASE INHIBITOR AND APPLICATION THEREOF | 中国药科大学 | 2020-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048914-A1 | PREPARATION FOR 6-AMINO-1H-PYRAZOLO[3,4-D]PYRIMIDINE-BASED JAK KINASE INHIBITOR AND APPLICATION THEREOF | JAK1, JAK3, SSB | JAK3 2/4885JAK1 1/4885JAK2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.